survey
Biomarker Identification a Challenge and Opportunity in Cancer Drug Development, Survey Finds
A survey of pharma professionals by contract research organization Icon found continued investment in precision drugs but varying views on their future impact.
The researchers also surveyed treating oncologists about why they decided to change, or not change, the treatment approach.
Despite Investments, Barriers Limit Access to Cutting-Edge Oncology Treatments, Survey Suggests
Cancer centers are investing in genetic testing and precision medicine experts, but Precision Oncology News' fifth annual survey suggests access challenges remain.
Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology
Precision Oncology News' 2022 survey showed doctors are increasingly offering molecular testing to earlier-stage patients, but institutions still need to do better to ensure patients have equitable access.
The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.